查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1908154

抗凝血剂市场规模、份额和趋势分析报告：按药物类别、给药途径、适应症、地区和细分市场预测，2026-2033年

Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category, By Route of Administration, By Application (Deep Vein Thrombosis, Pulmonary Embolism), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

抗凝血剂市场概述

2025年全球抗凝血剂市场规模估计为373.5亿美元，预计2033年将达557.2亿美元。

预计从 2026 年到 2033 年，其复合年增长率将达到 5.26%。心血管疾病（如深层静脉栓塞症(DVT)、肺动脉栓塞(PE) 和心房颤动 (AF)）的盛行率不断上升，预计将推动对抗凝剂的需求。

近年来，全球静脉血栓栓塞症（VTE）的发生率呈上升趋势。根据美国疾病管制与预防中心（CDC）统计，该疾病每年在美国影响多达90万人。 CDC也指出，每年约有6万至10万人死于静脉血栓栓塞症（VTE）。医疗专业人员倾向于使用抗凝血剂来预防血栓性栓塞症和中风等併发症。这些因素很可能导致抗凝血剂产业的需求显着增长。

久坐的生活方式、都市化加快、饮食习惯改变、缺乏运动等因素共同导致心血管疾病患者人数不断增加。静脉血栓栓塞症（VTE）也与其他多种疾病有关，包括癌症、复杂手术和怀孕。根据美国疾病管制与预防中心（CDC）统计，VTE是美国可预防性院内死亡的主要原因之一。鑑于这些因素，预计抗凝血药物的使用将持续成长。

抗凝血药物相关医疗技术的最新进展预计将推动市场成长。例如，罗氏（F. Hoffmann-La Roche）于2024年2月推出了一种新的Xa因子抑制剂凝血检测方法，旨在辅助临床医生製定口服直接抗凝血剂的处方决策，主要用于预防中风。此外，卒中发病率的上升预计也将推动预测期内的市场成长。血液凝固检验用于预防因各种疾病（例如心房颤动、某些瓣膜性心臟病和既往卒中）而有卒中风险的人群发生卒中。根据美国疾病管制与预防中心（CDC）统计，美国每年有超过79.5万人发生中风，其中约61万人为首次或新兴中风。

目录

第一章调查方法和范围

第二章执行摘要

第三章 抗凝血药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关及配套市场展望
  • 市场动态
  • 抗凝血剂市场分析工具
    • 产业分析：波特五力模型
    • PESTEL 分析

第四章：抗凝血药物市场：依药物类别分類的估算与趋势分析

  • 抗凝血药物市场：按药物类别分類的波动分析
  • 2021-2033年全球抗凝血剂市场规模及趋势分析（依药物类别划分）
  • 新型口服抗凝血剂（NOACs）
  • 维生素K拮抗剂
  • 直接凝血酶抑制剂
  • 肝素

第五章：抗凝血药物市场：依给药途径分類的估算与趋势分析

  • 抗凝血剂市场：按给药途径分類的差异分析
  • 2021-2033年全球抗凝血剂市场规模及趋势分析（依给药途径划分）
  • 口服抗凝血剂
  • 注射用抗凝血剂

第六章：抗凝血药物市场：依适应症分類的估算与趋势分析

  • 抗凝血剂市场：按适应症分類的差异分析
  • 全球抗凝血剂市场规模及趋势分析（依适应症划分，2021-2033年）
  • 心房颤动/心肌梗塞（心臟病发作）
  • 深层静脉栓塞症（DVT）
  • 肺动脉栓塞
  • 其他的

第七章：抗凝血药物市场：区域估算与趋势分析

  • 区域市场概览
  • 区域市场占有率分析（2025 年和 2033 年）
  • 抗凝血药物市场区域概览：主要结论
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 对主要市场参与企业近期趋势和影响的分析
  • 公司/竞争对手分类
  • 供应商概况
    • Key company heat map analysis, 2025
  • 公司简介
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
Product Code: GVR-4-68040-191-0

Anticoagulants Market Summary

The global anticoagulants market size was estimated at USD 37.35 billion in 2025 and is projected to reach USD 55.72 billion by 2033, growing at a CAGR of 5.26% from 2026 to 2033. The rising prevalence of cardiovascular diseases, such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Atrial Fibrillation (AF), is expected to drive demand for anticoagulants.

In recent years, a rise in venous thromboembolism (VTE) has been reported across various regions. According to the U.S. Centers for Disease Control and Prevention (CDC), in the U.S., up to 900,000 individuals are affected by it each year. CDC also states that nearly 60,000-100,000 fatalities are caused by venous thromboembolism (VTE) every year. Health professionals prefer using anticoagulants to prevent thromboembolic events and complications such as strokes. These aspects are likely to generate significant growth in demand in the anticoagulants industry.

A sedentary lifestyle, increasing urbanization, changing dietary preferences, and a lack of physical activity have contributed to the growing number of individuals experiencing cardiovascular diseases. VTE is also linked with multiple other conditions, including cancer, complicated surgeries, pregnancy, and others. According to the CDC, VTE is one of the leading causes of preventable hospital deaths in the U.S. Such aspects are expected to result in continuous growth in the adoption of anticoagulants.

Recent advancements in healthcare technology related to anticoagulants are anticipated to assist the market in growing. For instance, in February 2024, Roche (F. Hoffmann-La Roche Ltd.) launched novel Factor Xa inhibitor coagulation tests designed to facilitate clinical decisions regarding the prescription of direct oral anticoagulants, primarily for stroke prevention. Furthermore, the increasing incidence of stroke is projected to propel the market growth during the forecast period. Blood thinners are used for stroke prevention in individuals at risk due to various conditions, such as atrial fibrillation, certain heart valve disorders, and previous strokes. As per the CDC, over 795,000 individuals in the U.S. experience stroke every year, out of which approximately 610,000 are first-time or new strokes.

Global Anticoagulants Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the anticoagulants market report based on drug category, route of administration, application, and region:

  • Drug Category Outlook (Revenue, USD Million, 2021 - 2033)
  • Novel Oral Anticoagulants (NOACs)
    • Eliquis
    • Xarelto
    • Savaysa & lixiana
    • Pradaxa
  • Vitamin K Antagonist
  • Direct Thrombin Inhibitors
  • Heparin
    • Type
    • Low Molecular Weight Heparin
    • Ultra-low Molecular Weight Heparin
    • Unfractionated Heparin
    • Source
    • Porcine
    • Bovine
    • Others
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral Anticoagulants
  • Injectable Anticoagulants
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Atrial Fibrillation/Myocardial Infarction (Heart Attack)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism
  • Other Applications
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug category outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Segment Dashboard
  • 4.2. Anticoagulants Market: Drug Category Movement Analysis
  • 4.3. Global Anticoagulants Market Size & Trend Analysis, by Drug Category, 2021 to 2033 (USD Million)
  • 4.4. Novel Oral Anticoagulants (NOACs)
    • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.2. Eliquis
      • 4.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.3. Xarelto
      • 4.4.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.4. Savaysa & lixiana
      • 4.4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.4.5. Pradaxa
      • 4.4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5. Vitamin K Antagonist
    • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Direct Thrombin Inhibitors
    • 4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7. Heparin
    • 4.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.2. Type
      • 4.7.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.7.2.2. Low Molecular Weight Heparin
        • 4.7.2.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.7.2.3. Ultra-low Molecular Weight Heparin
        • 4.7.2.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.7.2.4. Unfractionated Heparin
        • 4.7.2.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.3. Source
      • 4.7.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.7.3.2. Porcine
        • 4.7.3.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.7.3.3. Bovine
        • 4.7.3.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.7.3.4. Others
        • 4.7.3.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.7.4. Others
      • 4.7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. Anticoagulants Market: Route of Administration Movement Analysis
  • 5.3. Global Anticoagulants Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 5.4. Oral Anticoagulants
    • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. Injectable Anticoagulants
    • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Anticoagulants Market: Application Movement Analysis
  • 6.3. Global Anticoagulants Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5. Deep Vein Thrombosis (DVT)
    • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Pulmonary Embolism
    • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Other Applications
    • 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2025 & 2033
  • 7.3. Anticoagulants Market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. China
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2025
  • 8.4. Company Profiles
    • 8.4.1. Aspen Holdings
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bristol-Myers Squibb Company
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Bayer AG
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Boehringer Ingelheim International GmbH
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. DAIICHI SANKYO COMPANY, LIMITED
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Johnson & Johnson Services, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Eisai Co., Ltd.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global anticoagulants market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 4 Global anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 5 Global anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 6 North America anticoagulants market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 8 North America anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 9 North America anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 10 U.S. anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 11 U.S. anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 12 U.S. anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 13 Canada anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 14 Canada anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 15 Canada anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 16 Mexico anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 17 Mexico anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 18 Mexico anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 19 Europe anticoagulants market, by country, 2021 - 2033 (USD Million)
  • Table 20 Europe anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 21 Europe anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 22 Europe anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 23 Germany anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 24 Germany anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 25 Germany anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 26 UK anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 27 UK anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 28 UK anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 29 France anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 30 France anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 31 France anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 32 Italy anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 33 Italy anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 34 Italy anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 35 Spain anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 36 Spain anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 37 Spain anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 38 Asia Pacific anticoagulants market, by country, 2021 - 2033 (USD Million)
  • Table 39 Asia Pacific anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 40 Asia Pacific anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 Asia Pacific anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 42 China anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 43 China anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 44 China anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 45 Japan anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 46 Japan anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 47 Japan anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 48 India anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 49 India anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 50 India anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 51 South Korea anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 52 South Korea anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 53 South Korea anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 54 Australia anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 55 Australia anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 56 Australia anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 57 Latin America anticoagulants market, by country, 2021 - 2033 (USD Million)
  • Table 58 Latin America anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 59 Latin America anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 60 Latin America anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 61 Brazil anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 62 Brazil anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 63 Brazil surgical anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 64 Argentina anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 65 Argentina anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 Argentina surgical anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 67 MEA anticoagulants market, by region, 2021 - 2033 (USD Million)
  • Table 68 MEA anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 69 MEA anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 70 MEA anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 71 South Africa anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 72 South Africa anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 73 South Africa anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 74 Saudi Arabia anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 75 Saudi Arabia anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 76 Saudi Arabia anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 77 UAE anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 78 UAE anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 79 UAE anticoagulants market, by application, 2021 - 2033 (USD Million)
  • Table 80 Kuwait anticoagulants market, by drug category, 2021 - 2033 (USD Million)
  • Table 81 Kuwait anticoagulants market, by route of administration, 2021 - 2033 (USD Million)
  • Table 82 Kuwait anticoagulants market, by application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Anticoagulants market: market outlook
  • Fig. 10 Anticoagulants competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Anticoagulants market driver impact
  • Fig. 16 Anticoagulants market restraint impact
  • Fig. 17 Anticoagulants market strategic initiatives analysis
  • Fig. 18 Anticoagulants market: Drug category movement analysis
  • Fig. 19 Anticoagulants market: Drug category outlook and key takeaways
  • Fig. 20 Novel Oral Anticoagulants (NOACs) market estimates and forecast, 2021 - 2033
  • Fig. 21 Eliquis market estimates and forecast, 2021 - 2033
  • Fig. 22 Xarelto market estimates and forecast, 2021 - 2033
  • Fig. 23 Savaysa & lixiana market estimates and forecast, 2021 - 2033
  • Fig. 24 Pradaxa market estimates and forecast, 2021 - 2033
  • Fig. 25 Vitamin K Antagonist market estimates and forecast, 2021 - 2033
  • Fig. 26 Direct Thrombin Inhibitors market estimates and forecast, 2021 - 2033
  • Fig. 27 Heparin market estimates and forecast, 2021 - 2033
  • Fig. 28 Low molecular weight heparin market estimates and forecast, 2021 - 2033
  • Fig. 29 Ultra-low molecular weight heparin market estimates and forecast, 2021 - 2033
  • Fig. 30 Unrationed heparin market estimates and forecast, 2021 - 2033
  • Fig. 31 Heparin sources market estimates and forecast, 2021 - 2033
  • Fig. 32 Porcine-based heparin market estimates and forecast, 2021 - 2033
  • Fig. 33 Bovine-based heparin market estimates and forecast, 2021 - 2033
  • Fig. 34 Other heparin market estimates and forecast, 2021 - 2033
  • Fig. 35 Others market estimates and forecast, 2021 - 2033
  • Fig. 36 Anticoagulants Market: Route of administration movement analysis
  • Fig. 37 Anticoagulants market: Route of administration outlook and key takeaways
  • Fig. 38 Oral anticoagulants market estimates and forecasts, 2021 - 2033
  • Fig. 39 Injectable anticoagulants market estimates and forecasts,2021 - 2033
  • Fig. 40 Anticoagulants market: Application movement analysis
  • Fig. 41 Anticoagulants market: Application outlook and key takeaways
  • Fig. 42 Atrial Fibrillation/Myocardial Infarction (heart attack) market estimates and forecasts, 2021 - 2033
  • Fig. 43 Deep Vein Thrombosis (DVT) market estimates and forecasts,2021 - 2033
  • Fig. 44 Pulmonary embolism market estimates and forecasts, 2021 - 2033
  • Fig. 45 Other applications market estimates and forecasts,2021 - 2033
  • Fig. 46 Global anticoagulants market: Regional movement analysis
  • Fig. 47 Global anticoagulants market: Regional outlook and key takeaways
  • Fig. 48 North America market estimates and forecasts, 2021 - 2033
  • Fig. 49 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 50 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 51 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 52 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 53 UK market estimates and forecasts, 2021 - 2033
  • Fig. 54 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 55 France market estimates and forecasts, 2021 - 2033
  • Fig. 56 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 57 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 58 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 59 China market estimates and forecasts, 2021 - 2033
  • Fig. 60 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 61 India market estimates and forecasts, 2021 - 2033
  • Fig. 62 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 63 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 64 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 65 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 66 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 68 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 70 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 71 Kuwait market estimates and forecasts, 2021 - 2033